Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Glaxo SmithKline

- PMLiVE

FDA clears Takeda’s vedolizumab for inflammatory bowel disease

Entyvio licensed for patients who have not responded to current therapies

- PMLiVE

GSK and Genmab’s Arzerra fails lymphoma trial

Cancer drug unable to beat Roche's MabThera in late-stage study

Novartis day

Novartis licenses Ophthotech eye drug in $1bn deal

Fovista is a potential first-in-class treatment for wet AMD

Novartis building

FDA rejects Novartis’ breakthrough heart failure drug

Regulator wants more data on serelaxin

Bristol-Myers Squibb (BMS) building

BMS’ nivolumab gets breakthrough status

But shares fall on concerns over new trial data

- PMLiVE

Second darapladib failure disappoints GSK

Drug unable to demonstrate effectiveness in acute coronary syndrome

China flag thumb

China targets UK exec in GSK corruption probe

Former GSK China manager Mark Reilly said to have ordered sales team to bribe doctors

- PMLiVE

Battle lines drawn as Allergan rejects Valeant offer

Turns down $47bn takeover bid saying it undervalues the company

Shire Basingstoke

Shire boosts rare disease portfolio with $260m Lumena deal

Acquisition of US company will bring two mid-stage candidates for rare liver diseases

- PMLiVE

GSK clear to launch COPD hope Anoro in Europe

Strengthens respiratory platform ahead of patent expiry for Advair/Seretide

EU flag

AbbVie’s hep C combo gets priority review in Europe

EMA to fast track drug for use in hard-to-treat genotype 1 strain of HCV

Novartis building

Novartis plans filings for acromegaly candidate

Could add to Signifor’s indications

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links